TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02249767
Drug: Tretinoin
Normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment of acne once daily in evening
Study: NCT02251925
Drug: administration of 6 mg Estradiol valerate
Normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the hormonal group without GnRH-a, endometrial preparation will be started with daily administration of 6 mg Estradiol valerate from the 2nd day of the natural menstrual cycle for 6 days. Then treatment will be continued similar to the 3rd group.
Study: NCT04393025
Drug: Optimum medical treatment
Normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimum Medical treatment
Study: NCT02652156
Drug: Exparel®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml Exparel (266 mg) will be drawn into a 20 ml syringe. A 20 ml Bupivacaine 0.25% syringe and the syringe containing the Exparel solution will be connected to the end of an IV extension set via a 3-way stopcock. The IV connection will be connected to the injection needle. The setup will be flushed with the Bupivacaine syringe. The TAP space will be located under ultrasound guidance. 133mg of Exparel will be injected into the TAP space. After injection, the syringe will be exchanged for the Bupivacaine syringe and 20ml Bupivacaine injected into the space. The process will be repeated on the opposite side TAP block.
Study: NCT00342849
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02465359
Drug: Immune Globulin Subcutaneous (Human)
Normalized name: immune globulin subcutaneous (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who have CIDP and are on IVIG will be allowed in the study to try subcutaneous immune Globulin (SCIG) as part of an open label study.
Study: NCT00689156
Drug: Epirubicin, cyclophosphamide and docetaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 90 mg/m2 iv day 1 every 3 weeks plus Cyclophosphamide 600 mg/m2 iv day 1 every 3 weeks times 3 followed by Docetaxel 100 mg/m2 iv day 1 every 3 weeks times 3
Study: NCT00689156
Drug: docetaxel, cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m2 plus cyclophosphamide 600 mg/m2 intravenously day 1 every 3 weeks times six
Study: NCT04774224
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will take one tablet of study drug per day for 48 weeks, and will be followed up for 48 weeks after study drug treatment has finished. One-third of participants will receive Placebo.
Study: NCT03027375
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo is manufactured by Beijing tcmages Pharmaceutical Co., Ltd. (Beijing, China) as well, following the Specification for processing Chinese medicine in Beijing. The placebo granules are similar in appearance, taste, and scent to the Qishen granules.
Study: NCT01657097
Drug: INCS
Normalized name: ZINC OXIDE 13 g in 100 mL TOPICAL LOTION [Zincscreen 100 Mineral SPF 40]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01657097
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01921855
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.
Study: NCT03882905
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one tablet, oral, once daily
Study: NCT03882905
Drug: Simivastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once daily administration at dose to be determined
Study: NCT03882905
Drug: Statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin administered orally once daily at dose determined by treatment prior to enrollment by personal physician
Study: NCT02703324
Drug: LY900014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously (SC)
Study: NCT00351910
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00891241
Drug: LMI 1195-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose, bolus IV injection of LMI 1195
Study: NCT01858766
Drug: SOF
Normalized name: Kasof
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg tablet administered orally once daily
Study: NCT00498589
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 25 mg per week IM or SC during 24 weeks
Study: NCT00498589
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one intramuscular injection per week
Study: NCT01979952
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice daily dosing
Study: NCT01483183
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo dose, 10-minute constant rate IV infusion
Study: NCT02389036
Drug: SDD Oral Paste
Approvals — FDA: no, EMA: no, PMDA: no
Description: A six-hourly topical application of 0.5g paste, containing colistin 10mg, tobramycin 10mg and nystatin 125,000 IU, to the buccal mucosa and oropharynx
Study: NCT02389036
Drug: SDD Gastric Suspension
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2. A six-hourly administration of 10 mL of a suspension containing 100 mg colistin, 80 mg tobramycin and 2 x 10 \^6 IU nystatin, to the gastrointestinal tract via a gastric/post-pyloric tube
Study: NCT02389036
Drug: Intravenous Antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: A four-day course of an intravenous antibiotic in patients not already receiving a therapeutic antibiotic
Study: NCT00320021
Drug: Pyridorin (pyridoxamine dihydrochloride)
Normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02338622
Drug: AZD5363
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD5363 BD
Study: NCT00003512
Drug: Antineoplaston therapy (Atengenal + Astugenal)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT01683825
Drug: F-18 florbetapir PET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac PET images will be obtained following injection of F-18 labeled Florbetapir (Trade Name: Amyvid)
Study: NCT04518540
Drug: control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients will take domestic riluzole tablets 50mg orally, twice a day.
Study: NCT01379196
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tab. Azithromycin 500 mg PO three times weekly for 3 months
Study: NCT00098579
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00269867
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be adminstered at Week 0, 2, 6 and every 4 weeks up to Week 54.
Study: NCT01919801
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01638117
Drug: PAC14028-0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAC-14028 Cream, 0.1%, Daily for up to 21 days
Study: NCT01638117
Drug: PAC14028-0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAC-14028 Cream, 0.3%, Daily for up to 21 days
Study: NCT01638117
Drug: PAC14028-1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAC-14028 Cream, 1%, Daily for up to 21 days
Study: NCT01843062
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 capsules ( to match Selumetinib capsules) orally twice a day for approximately 5 weeks treatment period
Study: NCT01185925
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02365506
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match tablets administered orally in a single dose
Study: NCT01294683
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01294683
Drug: Extended Release (ER) niacin/laropiprant/simvastatin (N/LRPT/SIM)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01294683
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00759330
Drug: Flurbiprofen Tape (Arm 2)
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two flurbiprofen tapes (one on each side of the spine) were applied on the lower back area once daily for 7 days. Each tape contained 31.5 mg flurbiprofen for a total daily dose of 63 mg.
Study: NCT00759330
Drug: Placebo Tape (Arm 3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two placebo tapes (one on each side of the spine) were applied on the lower back area once daily for 7 days.
Study: NCT00759330
Drug: Flurbiprofen Tape (Arm 4)
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two flurbiprofen tapes (one on each side of the spine) were applied on the lower back area once daily for 7 days. Each tape contained 31.5 mg flurbiprofen for a total daily dose of 63 mg.
Study: NCT02470325
Drug: Avidekel oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avidekel cannabis oil 6:1 CBD:THC
Study: NCT02470325
Drug: Enriched Avidekel oil
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enriched Avidekel cannabis oil 20:1 CBD:THC
Study: NCT03067155
Drug: Standard anti-viral therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue with the anti-viral treatment as per standard of care.
Study: NCT01498588
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neoadjuvant eribulin followed by dose-dense doxorubicin and cyclophosphamide
Study: NCT01498588
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Neoadjuvant eribulin followed by dose-dense doxorubicin and cyclophosphamide
Study: NCT02186665
Drug: placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01907763
Drug: SOTB07 200mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01907763
Drug: SOTB07 400mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01907763
Drug: SOTB 200mg placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of SOTB07 200mg
Study: NCT01907763
Drug: SOTB 400mg placebo
Normalized name: placebo 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of SOTB07 400mg
Study: NCT00716846
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10mg, 2 weeks
Study: NCT01251120
Drug: DMARD
Normalized name: Disease-modifying antirheumatic drug (DMARD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-biologic DMARDs (including methotrexate) according to current best practice
Study: NCT00628134
Drug: isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: single inhaled dose by nebulizer
Study: NCT01524341
Drug: KAE609
Approvals — FDA: no, EMA: no, PMDA: no
Description: KAE609 was supplied as capsules for oral use.
Study: NCT01227863
Drug: MAXINOM®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone...............................................0,1% Neomicyn......................................0,35% polimixyn B...................................0,1%
Study: NCT01227863
Drug: Maxitrol®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone...............................................0,1% Neomicyn......................................0,35% Polimixyn B...................................0,1%
Study: NCT01247194
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules, oral, once daily for 3 days
Study: NCT03558256
Drug: Medication
Normalized name: Acne Medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both of the MBCT group and the medication group will receive the medication treatment. The initial dose conforms the drug instructions, the dosage can be adjusted once a week, and the maximum dosage should not exceed the maximum amount by the instructions. MDD patients with sleep disorders can use drugs combined with benzodiazepine drugs, but not continuing for more than two weeks; while other psychotropic drugs are not allowed. All of the drugs used in this study are usual clinical drugs with good security, the common adverse reactions include nausea, dry mouth, constipation, diarrhea, indigestion, dizziness, drowsiness, fatigue, sweating, heart palpitations, delayed ejaculation in male, increasing blood aminotransferase without symptoms occasionally and so on.
Study: NCT01387230
Drug: GSK573719
Approvals — FDA: no, EMA: no, PMDA: no
Description: 62.5 mcg
Study: NCT01387230
Drug: GSK573719
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125mcg
Study: NCT01807923
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablet
Study: NCT02371603
Drug: GSK1278863 25 mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: A round, biconvex, white film coated tablet to be taken orally in the fasted state in the morning
Study: NCT02371603
Drug: Rosuvastatin 10 mg Tablet
Normalized name: rosuvastatin 10 MG
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pink, round, biconvex, coated tablets. Debossed CRESTOR and 10 on one side, to be taken orally in the fasted state in the morning
Study: NCT01605981
Drug: AMN107
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03854396
Drug: Prasterone
Normalized name: Prasterone
DrugBank: Prasterone sulfate (DB05804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nightly intravaginal prasterone insert (6.5 mg prasterone at a concentration of 0.50%) for 24 weeks.
Study: NCT02678416
Drug: IV Acetaminophen (Treatment A)
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen administered by intravenous (IV) infusion
Study: NCT02678416
Drug: Oral Acetaminophen (Treatment B)
Normalized name: acetaminophen Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen administered by oral tablets
Study: NCT02678416
Drug: Placebo (Treatment C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered by IV infusion or oral tablets
Study: NCT00195663
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00195663
Drug: Methotrexate placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04659525
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the placebo arm placebo subcutaneous every 2 weeks will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia
Study: NCT04551950
Drug: M7824
Normalized name: M7824
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received bintrafusp alfa until confirmed disease progression, death, unacceptable toxicity and study withdrawal maximum of 2 years (at the discretion of the Investigator).
Study: NCT02639520
Drug: Canephron® N
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets 3 times a day for 7 days
Study: NCT02639520
Drug: Canephron® N-placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets 3 times a day for 7 days
Study: NCT02406105
Drug: CyberKnife
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03301298
Drug: SXC-2023
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT03301298
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo given as oral capsule.
Study: NCT03270332
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhalation of placebo through a spacer
Study: NCT02073734
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo given IV
Study: NCT02112864
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mL normal saline
Study: NCT02451943
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered IV
Study: NCT02451943
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT00658463
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: rosuvastatin 20 mg/day during 6 weeks versus placebo during 6 weeks in a cross-over design
Study: NCT00658463
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04666454
Drug: Adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine infusion 70 µg/kg/min for 3 hours.
Study: NCT01272947
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical gel 1%- 4 times daily
Study: NCT02624778
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT04117009
Drug: Remifentanil 2 MG
Normalized name: remifentanil 2 MG
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once the participants transferred to operating room, electrocardiography, noninvasive blood pressure, pulse oximetry, and respiratory rate will be recorded. An increase or decrease from the baseline value of 30% in mean arterial pressure will be treated with iv boluses of (5 mg) ephedrine or glyceryl trinitrate (25 micg). All the participants will undergo a baseline transthoracic echocardiographic evaluation to assess the systolic and diastolic function of the left ventricle before the infusion of the study drug. Then the patients will be given oxygen by a face mask at a rate of 5-6 L/min, and Remifentanil infusion will be started using a target controlled infusion pump to reach a target plasma concentration of 2 ng/mL. Once the target concentration is reached, second echocardiographic evaluation to assess the systolic and diastolic function will be performed. Potential side effects of Remifentanil will be monitored.
Study: NCT04193878
Drug: Inhaled placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: aerosolized saline (4 ml of 0.9% saline) twice daily for up to 5 days
Study: NCT04445181
Drug: The physician's prescription in routine clinical practice
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an Observational study that will not involve prescription of the drugs.
Study: NCT01180296
Drug: Identical Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical Placebo tablet = placebo taking nightly from 16 to 34 weeks
Study: NCT03770780
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in combination with Ketamine
Study: NCT01406977
Drug: BPS804
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03764345
Drug: Sofosbovir/Lepipasvir (200/45mg) tablet (Heterosofir)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive oral daily dose of Sofosbovir/Ledipasvir (200/45mg) daily for 8 weeks
Study: NCT01375361
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5mg Normal Saline inhaled on enrollment and at 4 hours in emergency department.
Study: NCT00388011
Drug: Intranasal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal placebo
Study: NCT00093795
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles~Group 2 and Group 3: cyclophosphamide 600 mg/m2 IV every 14 days for 4 cycles
Study: NCT00093795
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group 1: 50 mg/m2 IV every 21 days for 6 cycles~Group 2 and Group 3: 60 mg/m2 IV every 14 days for 4 cycles
Study: NCT04173065
Drug: VK2809
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule
Study: NCT04173065
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule
Study: NCT00930228
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, for oral administration, twice a day for 4 weeks (or menstrual cycle length in normally-cycling controls)
Study: NCT00460551
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cisplatin and docetaxel administered as two cycles given every three weeks
Study: NCT00606866
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for four weeks
Study: NCT01306331
Drug: Conceptrol
Normalized name: Conceptrol
Approvals — FDA: no, EMA: no, PMDA: no
Description: • Conceptrol® Vaginal Gel, which contains 100 mg (4% concentration) of nonoxynol-9 (N-9) in 2.5 mL volume of gel.
Study: NCT00680823
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mL IM to each side in to the lower cervical paraspinous muscles x 1.
Study: NCT03606837
Drug: 68Ga-PSMA-617 PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET/CT Imaging with 68Ga-PSMA-617 injection
Study: NCT03606837
Drug: 68Ga-RM2 PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET/CT Imaging with 68Ga-RM2 injection
Study: NCT04338828
Drug: Nitric Oxide Gas
Normalized name: Nitric oxide gas
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled NO administered at target inspired concentration 140 - 300 ppm for 20-30 minutes
Study: NCT01211665
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisolone used as a taper, with suggested dosages starting at 80 mg and tapering to 5 mg.
Study: NCT04565249
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04519281
Drug: IV of vitamin C
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of high-dose of IV vitamin C perioperatively
Study: NCT03152591
Drug: LIK066
Approvals — FDA: no, EMA: no, PMDA: no
Description: LIK066 tablets for oral administration
Study: NCT03152591
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets matching LIK066 tablets, for oral administration